Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
An article from
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK’s return to neuroscience.
Published July 9, 2026
A GSK logo is seen on the side of an office building in Poznan, Poland.
Getty Images
GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline…
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration…
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an…
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access…
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
Merck ends a Phase 2 Alzheimer's trial for MK-1167, partnered with Neuphoria Therapeutics, after the drug missed efficacy…
